High-dose interleukin-2 is an intensive treatment regardless of the venue of administration

Cancer Journal

Volumn 7, Issue 2, 2001, Pages 103-104

  Schwartzentruber, D J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG SAFETY; HUMAN; INTENSIVE CARE UNIT; KIDNEY CARCINOMA; NOTE; PRIORITY JOURNAL; TREATMENT INDICATION;

CARCINOMA, RENAL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS;

EID: 0035051481     PISSN: 15289117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (5)

1. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy
2. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: Identification of the antigens mediating response
3. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer
4. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy
5. Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma